Alto Neuroscience, Inc.
Alto Neuroscience is a U.S. clinical-stage biotechnology company developing precision medicines for neuropsychiatric disorders. Its research strategy uses patient biomarkers and related analytical approaches to identify groups that may respond to particular therapies. The company's therapeutic emphasis includes depression and other disorders of the central nervous system, with development work involving targeted small-molecule candidates. Alto is based in Mountain View, California, and trades on the New York Stock Exchange under ANRO. The company's scientific approach is centered on matching treatments to patient biology rather than relying only on broad diagnostic categories.
Company at a glance
Corporate information
- Company entity
- Alto Neuroscience, Inc.
- Headquarters / principal office
- United States
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.altoneuroscience.com/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
NYSE: ANRO
biomarker guided precision psychiatry · small molecules
neuropsychiatry · depression · central nervous system
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Alto Neuroscience is a U.S. clinical-stage biotechnology company developing precision medicines for neuropsychiatric disorders. Its research strategy uses patient biomarkers and related analytical approaches to identify groups that may respond to particular therapies. The company's therapeutic emphasis includes depression and other disorders of the central nervous system, with development work involving targeted small-molecule candidates. Alto is based in Mountain View, California, and trades on the New York Stock Exchange under ANRO. The company's scientific approach is centered on matching treatments to patient biology rather than relying only on broad diagnostic categories.
Business, technology & evidence
- SecuritiesNYSE: ANRO
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Alto Neuroscience, Inc. ↗Alto Neuroscience, Inc. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.